Trial Profile
first-in-human,single center, open-label study of Pharmacokinetics, Safety and Tolerability of the Iminosugar Sinbaglustat
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2021
Price :
$35
*
At a glance
- Drugs Sinbaglustat (Primary)
- Indications CNS disorders; Lysosomal storage diseases; Renal impairment
- Focus Adverse reactions; First in man; Pharmacokinetics
- 23 Dec 2020 Results published in the Journal of Clinical Pharmacology
- 08 Oct 2020 Status changed from recruiting to completed, according to an Idorsia Pharmaceuticals media release.
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting